Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic pathways without systematic methodology or original empirical human data.
PubMed 25987424 · doi:10.1016/j.ejphar.2015.03.092
What was done
This narrative review synthesizes research on the structure-function, biosynthesis, and biological pathways of specialized pro-resolving mediators (SPMs)—including E-series resolvins derived from EPA, as well as D-series resolvins, protectins, and maresins derived from DHA—focusing on persistent adipose tissue inflammation and liver disease associated with obesity and metabolic syndrome.
What was found
The abstract reports no numerical findings or quantitative effect estimates. It outlines qualitative mechanistic actions, noting that SPMs function as stop-signals for inflammation, promote macrophage efferocytosis (clearance of apoptotic cells), and facilitate macrophage efflux to lymph nodes.
Why it matters
It details the biological mechanisms by which omega-3 fatty acid metabolites mediate active inflammation resolution, highlighting potential therapeutic strategies for chronic obesity-linked metabolic and hepatic disorders.
Limits
This is a non-systematic narrative review providing no primary clinical trial data, quantitative metrics, or methodology regarding study selection.
Cited by
- supports Specialized pro-resolving mediators (SPMs) such as maresins, protectins, and resolvins are metabolites of EPA and DHA that actively resolve inflammation.